Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company present new linagliptin data at American Diabetes Association's 72nd Scientific Sessions®
06:05 EDT 9 Jun 2012 | PR Newswire
This article has expired, however you can still
download the PDF.
Preview:
RIDGEFIELD, Conn. and INDIANAPOLIS, June 9, 2012 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) presented results from two randomized phase 3 clinical trials and a post-hoc analysis for linagliptin at ...
Other Sources for this Article
More From BioPortfolio on "Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company present new linagliptin data at American Diabetes Association's 72nd Scientific Sessions®"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
